Ozempic has become one of the most talked-about drugs in the country, prescribed for both type 2 diabetes and weight loss. But behind the hype, serious risks are coming to light. Lawsuits have already tied Ozempic, Wegovy, and similar medications to gastroparesis, bowel blockages, and other severe complications. Now, a new wave of claims is emerging: an Ozempic vision lawsuit. Reports link Ozempic, Wegovy, Mounjaro, Rybelsus, and Zepbound to sudden vision loss. Patients are now filing an Ozempic blindness lawsuit after reports linked Ozempic and similar drugs to sudden vision loss.
Researchers have connected these drugs to a condition called non-arteritic anterior ischemic optic neuropathy or NAION. Some doctors even refer to it as an “eye stroke.” It happens when blood flow to the optic nerve is cut off, which can lead to sudden and sometimes permanent vision loss with little to no warning.
If you’ve noticed blurred vision, sudden loss of sight, or other serious eye problems after using Ozempic or similar medications, it may be connected. In the sections ahead, we’ll walk through what’s happening with these vision loss cases, which drugs are involved, and the options available if this has touched your life.
Ozempic (semaglutide) is a weekly injection that comes in a prefilled pen. Doctors often prescribe it to adults with type 2 diabetes to help manage blood sugar. The drug belongs to a class called GLP-1 receptor agonists, which copy the action of a natural hormone that lowers blood sugar by boosting insulin and reducing glucose release.
Novo Nordisk, a Danish pharmaceutical company, developed Ozempic in 2012. Today, it’s the only company in the U.S. with FDA-approved semaglutide products: Ozempic®, Wegovy®, and Rybelsus®. The FDA first approved Ozempic in 2017 for type 2 diabetes.
Ozempic and Wegovy are both given as weekly injections, but they serve different purposes. Ozempic is prescribed for type 2 diabetes in smaller doses (0.5 to 1 mg per week). Wegovy, on the other hand, is approved for weight loss at a higher dose (2.4 mg per week). Rybelsus is another semaglutide option, but instead of injections, it comes as a daily pill (3 mg, 7 mg, or 14 mg).
Even though Ozempic isn’t FDA-approved for weight loss, many patients using it for diabetes end up losing weight. Semaglutide works by slowing down digestion, which keeps you feeling full longer and usually leads to eating less without really trying.
Patients taking Ozempic or similar medications need to pay close attention to their eye health. While these drugs are meant to help manage blood sugar and, in some cases, aid in weight loss, they have also been linked to other serious side effects in the past, like gastroparesis, bowel blockages, nausea, and dehydration. Now, eye-related issues are emerging as another concern.
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION happens when blood flow to the optic nerve is reduced, causing permanent damage to the nerve that connects your eye to your brain. Symptoms may include:
People over 50, those with diabetes, high blood pressure, high cholesterol, sleep apnea, certain eye anatomies, or those taking medications like semaglutide (Ozempic) or sildenafil (Viagra) may have higher risks.
Eye Floaters
Floaters appear as small spots, lines, or cobweb-like shapes in your vision, often noticeable against bright backgrounds. They can be caused by:
Ozempic may contribute to floaters through changes in blood sugar, dehydration, diabetic retinopathy, or inflammatory responses.
Dry Eyes
Dry eye syndrome happens when your eyes don’t produce enough tears or tears evaporate too quickly, causing stinging, burning, blurred vision, light sensitivity, and general discomfort. While not a listed side effect, Ozempic may play a role by:
Eye Twitching
Eyelid twitching (myokymia) is usually temporary but can recur. Causes include stress, fatigue, caffeine, eye strain, nutritional deficiencies, and allergies. Ozempic may be linked to twitching through:
Other Potential Eye Issues
Patients may also notice:
Recent research has raised concerns that Ozempic, Wegovy, Mounjaro, and similar drugs may increase the risk of sudden vision problems. Doctors are particularly watching a condition called non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an “eye stroke,” which can cause permanent damage to the optic nerve.
2024 Danish/Norwegian Cohort Study
Following over 400,000 diabetes patients, researchers found that those taking semaglutide had more than double the risk of NAION compared to other diabetes medications. The absolute risk remains low, but the increase is significant for affected individuals. Early signals suggest Wegovy may carry a similar risk.
2024 Meta-analysis of Clinical Trials
Data pooled from multiple trials, including those run by Novo Nordisk, confirmed an increased risk of optic nerve injury among patients using GLP-1 drugs like Ozempic. Further research is still needed to understand the full extent.
Katz et al. Case Series (University at Buffalo)
A small series of real-world cases found that seven out of nine patients on GLP-1 drugs developed NAION or other serious vision issues, supporting the evidence seen in larger studies.
Mass Eye and Ear Study (Rutgers/Harvard)
Among diabetic patients using semaglutide, 8.9% developed NAION compared to 1.8% on other treatments. For overweight or obese patients, 6.7% developed NAION versus 0.8% on alternative therapies. These numbers highlight the severity and permanent nature of the condition.
July 2024 JAMA Ophthalmology Study
This peer-reviewed study confirmed a clear link between GLP-1 drugs and increased NAION risk, emphasizing the importance of monitoring and patient education.
December 2024 JAMA Ophthalmology Longitudinal Study
A five-year follow-up study in Denmark found that weekly semaglutide use more than doubled the risk of NAION compared to other diabetes treatments. It highlighted the need for careful monitoring, particularly for high-risk patients.
NAION is rare, but the effects can be permanent. There’s no way to reverse the damage, so it’s important to notice any vision changes early and report them to a doctor.
When reports connected Ozempic to sudden vision loss, Novo Nordisk addressed the concerns by saying the evidence isn’t strong enough to show a direct link between semaglutide and NAION. A company spokesperson noted that NAION isn’t listed as a side effect on Ozempic’s approved label and mentioned that some studies, like the one from Mass Eye and Ear, had small sample sizes and weren’t randomized. They also stressed that patient safety is a top priority and that all reports of adverse events are taken seriously.
Some people who took Ozempic or similar drugs like Wegovy and Rybelsus have suddenly experienced serious eye problems, including vision loss. Many of them are now pursuing legal action, saying that Novo Nordisk did not clearly warn about NAION, a rare condition that can lead to permanent blindness.
Losing vision can turn everyday life challenging. Things like driving, working, and even simple daily tasks can become much harder. These cases aim to hold the company responsible and help people cover medical costs, lost wages, and other challenges caused by their injuries.
The lawsuits are still moving through the courts. Some are being handled together in a multidistrict litigation to keep the process organized, while others are moving forward in state courts. For those affected, the focus is on getting fair compensation for the very real impact on their lives.
Patients experiencing vision problems or optic nerve damage have been linking their injuries to these medications:
These drugs are widely prescribed and often seen as safe but reports of sudden vision loss and other serious eye issues have raised real concerns for people taking them.
The number of lawsuits tied to Ozempic, Wegovy, and Rybelsus continues to climb. In July 2025, more patients came forward claiming the drugs caused NAION (non-arteritic anterior ischemic optic neuropathy), a condition that can lead to sudden and permanent blindness. Here are the latest developments:
August 15, 2025 – Major Ruling
Judge Karen Spencer Marston ruled that gastroparesis claims must be backed by gastric emptying studies. While this limits some cases, she allowed safety and labeling claims to move forward, keeping the core litigation alive.
August 1, 2025 – New Legal Options
A request in New Jersey seeks to consolidate NAION lawsuits into a multicounty litigation. Meanwhile, federal MDL 3072 has grown to 2,190 pending cases.
July 29, 2025 – NJ Vision Loss Cases Grow
More than 30 plaintiffs from 13 states have petitioned for a mass tort in Middlesex County over NAION claims, up from 21 in June.
July 28, 2025 – New Study
A Swedish study found Ozempic users had a 1.6 times higher risk of retinal vein occlusion, a condition that can cause sudden vision loss.
July 19, 2025 – Vision Track Requested
Plaintiffs asked the MDL court to create a separate track for over 140 cases involving blindness and other vision injuries.
July 15, 2025 – Texas Blindness Case
A woman in Texas sued Novo Nordisk after losing 90% of the vision in one eye, alleging Ozempic triggered NAION after six months of use.
June 24, 2025 – New Study Links Ozempic to Macular Degeneration
A JAMA Ophthalmology study found semaglutide users were twice as likely to develop neovascular age-related macular degeneration (nAMD), a disease that causes permanent central vision loss. While the absolute risk was small, the findings are statistically significant and biologically plausible, adding to growing concerns about GLP-1 drugs and eye health.
June 21, 2025 – New NJ Lawsuit
A man from Woodbridge, NJ, filed suit alleging Wegovy caused NAION and permanent blindness. He claims Novo Nordisk failed to warn about the risk of optic nerve damage.
June 17, 2025 – Push for Consolidation
Twenty-one New Jersey plaintiffs are seeking to combine their NAION lawsuits into a multicounty litigation. Vision loss claims are quickly becoming more prominent than the original gastroparesis lawsuits because the injuries are so severe and life-changing.
June 12, 2025 – MDL Case Count
The GLP-1 MDL (3094) in Pennsylvania now has 1,882 pending cases, mostly involving gastroparesis. More NAION cases are expected, especially once the court rules on expert evidence.
June 10, 2025 – Calls for FDA Black Box Warning
Ophthalmologists and public health advocates are urging the FDA to add a black box warning about NAION to Ozempic, Wegovy, and Rybelsus. Recent studies in JAMA Ophthalmology and Danish registries support a link to sudden vision loss. A warning would strengthen plaintiffs’ claims that Novo Nordisk knew about the risk but failed to act.
June 2, 2025 – Novo Nordisk Defense Strategy
In early filings, Novo Nordisk argued that plaintiffs’ vision loss may stem from underlying conditions like diabetes, high blood pressure, or cholesterol, not semaglutide. Plaintiffs’ attorneys counter that even a small added risk should have been disclosed, and emerging data shows NAION cases are higher than expected, even among patients with no prior eye issues.
May 19, 2025 – Vision Loss Lawsuits
New cases allege Ozempic, Wegovy, and Rybelsus caused NAION, a condition that can lead to blindness. Plaintiffs say Novo Nordisk failed to warn despite mounting evidence. Because blindness is permanent, these cases may carry higher value than the GI injury suits.
April 22, 2025 – Dismissal Arguments
Novo Nordisk and Eli Lilly asked the court to dismiss claims as vague. Plaintiffs argued their complaint is detailed, citing specific injuries and misleading marketing. The judge’s ruling will be a turning point.
April 21, 2025 – CDC Study Released
A CDC-backed study tied semaglutide to 25,000 ER visits in 2022–23, nearly half requiring hospitalization. Defendants may argue the risks are rare, but the data underscores the severity.
April 9, 2025 – Expert Challenges
Defense lawyers want gastroparesis claims thrown out unless backed by a gastric emptying study. Plaintiffs say many cases were diagnosed without the test because symptoms eased after stopping the drug.
March 26, 2025 – New Lawsuit Filed
An Illinois woman sued Novo Nordisk directly in the MDL, claiming Ozempic caused debilitating gastroparesis. She says the company knew about the risks but failed to warn.
March 17, 2025 – Eli Lilly Motion
Lilly asked the court to require “objective testing” to prove gastroparesis, aiming to block expert testimony that symptoms and clinical judgment alone can be enough. Plaintiffs argue this is an unrealistic legal hurdle meant to cut claims.
February 26, 2025 – Vision Risk Study
A JAMA Ophthalmology study of 37 million adults found semaglutide users had higher rates of NAION (14.5 cases per 100,000), a condition that can cause sudden blindness. Researchers recommend doctors warn patients of this risk.
January 28, 2025 – Thyroid Cancer Study
JAMA Otolaryngology published a study linking GLP-1 drugs like Ozempic and Mounjaro to increased thyroid cancer diagnoses within the first year. While not conclusive, it raises more safety concerns.
January 22, 2025 – Broader Risk Study
A new study showed that while GLP-1 drugs may lower risks of dementia and heart disease, they’re also linked to serious issues like GI disorders, kidney stones, arthritis, and pancreatitis. Researchers stress the need for stronger safety warnings.
December 31, 2024 – MDL Growth and Key Hearing Set
At year’s end, plaintiffs’ lawyers estimated nearly 7,000 potential cases under investigation, with projections of tens of thousands more. Judge Marston scheduled a May 20, 2025, hearing to address early discovery, preemption, label adequacy, and diagnostic standards for gastroparesis.
December 20, 2024 – Saxenda Added
The JPML expanded the MDL to include Saxenda-related claims but rejected blood clot injury cases, keeping the focus on gastrointestinal injuries like gastroparesis and intestinal blockages.
November 13, 2024 – New Case Filed
A Tennessee woman filed suit after developing confirmed gastroparesis, diagnosed with a gastric emptying study. She claims Novo Nordisk downplayed GI risks while promoting Ozempic and Wegovy as safe weight-loss solutions.
November 12, 2024 – Downplaying Risks
Plaintiffs say Novo Nordisk knew about gastroparesis risks but avoided updating labels, fearing it would scare off patients. Lawyers now see gastroparesis as the centerpiece of the litigation.
November 4, 2024 – Diagnostic Proof in Focus
Judges and lawyers are zeroing in on gastric emptying studies as the strongest evidence of gastroparesis. These tests will likely play a central role in proving claims going forward.
November 1, 2024 – Court Deadlines
Judge Marston set a schedule:
October 29, 2024 – FDA Flags Production Issues
The FDA cited Novo Nordisk’s main Denmark plant, one of only two sites making semaglutide, for failing to properly monitor water used in production. Its North Carolina facility had earlier been flagged for poor bacterial controls. Critics say Novo is rushing to meet demand and cutting safety corners.
September 16, 2024 – Vision Problems Raise Alarms
The American Academy of Ophthalmology warned that Ozempic and similar drugs may lead to blindness through conditions like diabetic retinopathy, eye strokes, or NAION. These risks are now becoming a bigger focus in the lawsuits.
July 3, 2024 – Blindness Risk Study Published
A study linked Ozempic to NAION, a rare eye stroke causing sudden blindness. Doctors reported three cases in one week. Diabetics on the drug faced four times the risk, while overweight non-diabetics faced seven. The FDA is reviewing if blindness should be added to the warning label.
June 2024 – New Judge Assigned
After Judge Gene E.K. Pratter’s passing, Hon. Karen Spencer Marston was appointed to oversee MDL 3094 (Ozempic lawsuits). At a June 10 hearing, she issued case management orders to streamline filings. This is her first multidistrict litigation case.
May 17, 2024 – Judge Pratter Passes Away
Judge Gene E.K. Pratter, who had been presiding over the Ozempic lawsuits, died at 75 from chronic obstructive pulmonary disease. She was respected for her commitment to fairness in the judicial system and had served both as a federal judge and law professor.
February 2024 – Ozempic MDL 3094 Created
On Feb. 2, 2024, the JPML consolidated all GLP-1 drug lawsuits, including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro, into MDL 3094 in the Eastern District of Pennsylvania, citing shared claims of gastrointestinal injuries and failure to warn. Judge Gene E.K. Pratter was assigned to oversee the cases, with thousands more expected. On Feb. 15, the Court set its first conference for March 14 to discuss leadership and scheduling. A week later, CMO #2 outlined special pro hac vice requirements for attorneys joining the MDL.
January 2024 – Early Research on Eye Risks
A systematic review linked semaglutide to blurred vision, retinopathy, and macular complications, highlighting the need for more study.
August 2021 – Retinopathy Concerns
A study found semaglutide users with existing diabetic retinopathy faced higher risks of complications, possibly tied to rapid drops in blood sugar.
June 2020 – Initial Findings
Research showed Ozempic had higher rates of diabetic retinopathy (16.4%) and ocular issues (1.1%) compared to other GLP-1 drugs.
You may qualify if:
Call Ethen Ostroff Law to see if you qualify.
Act quickly if you’ve been taking Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and notice vision changes. Early attention can help protect your eyesight and keep your options open if you need to take legal steps.
See a Doctor Right Away
If your vision becomes blurry, you have trouble focusing, or you suddenly lose sight, contact your healthcare provider as soon as possible. They can check for problems like optic nerve damage or diabetic eye complications and figure out if your medication might be involved.
Get a Thorough Eye Exam
Your doctor may refer you to an eye specialist. Regular exams are important if you’re on medications that could affect your eyes, or if your symptoms are getting worse. Eye specialists can track changes and recommend needed treatment.
Keep Track of Everything
Write down any changes in your vision, when they happen, and how bad they are. Save your test results and notes from appointments. This record can help your doctors and may be important if you decide to pursue an Ozempic blindness lawsuit.
Talk to an Ozempic Lawyer
If you think your vision problems are linked to Ozempic or other semaglutide drugs, talking to a lawyer who handles these cases can help. Lawyers at Ethen Ostroff Law can review your situation, explain your options, and assess if you qualify for an Ozempic vision loss lawsuit.
If you’ve noticed vision problems after taking Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, here’s a practical approach:
Talk to a lawyer experienced in Ozempic vision loss lawsuits
Start with a consultation. A qualified attorney can confirm if you qualify and explain any deadlines for filing a personal injury claim.
Gather your records
Collect medical reports, prescriptions, doctor’s notes, test results, and bills. Anything showing you took a semaglutide drug and experienced NAION or other vision problems helps support your Ozempic blindness lawsuit.
Stay involved with your lawyer
Keep your attorney updated and provide any details they need. This helps them prepare a clear, strong Ozempic lawsuit for you.
Consider settlement or trial options
Your lawyer will guide you if it’s better to negotiate a settlement or take your lawsuit against Ozempic to trial. Some cases resolve faster through negotiation, while others proceed to court.
Compensation
If your case succeeds, you may recover funds for medical expenses, lost wages, and other damages caused by vision loss.
Careful documentation is key. Clear records show the full impact of your health issues and help your lawyer make the strongest Ozempic vision loss lawsuit.
Gather any records that show how Ozempic or similar drug affected your vision to give your lawyer a clear picture of what happened:
Have these ready to help your lawyer understand your case and support your claim.
If your Ozempic blindness lawsuit is successful, you could be eligible for compensation that covers the real impact this has had on your life, including:
This compensation is meant to help cover the financial and personal toll caused by vision damage from these medications.
You have a limited time to file a claim. The window in most states is usually two to three years from when you first noticed vision problems or realized they could be linked to the medication. In Pennsylvania, the typical deadline is three years. Consult with a lawyer at Ethen Ostroff Law as soon as possible to avoid missing your opportunity to pursue a claim.
If you’ve experienced vision problems from Ozempic or other semaglutide drugs, reach out to an Ozempic lawyer at Ethen Ostroff Law as soon as possible. Filing a claim has time limits—most states only allow 2-3 years from when your vision issues started or when you discovered a link to the medication. Acting quickly helps make sure you don’t miss your chance to seek compensation.
We handle cases involving the Ozempic class action lawsuit, Mounjaro blindness, Ozempic Wegovy blindness, and Ozempic blurry vision. We’ll guide you through the process, help gather the necessary medical records and explain your options, so you have the best chance to recover damages for medical bills, lost income, and other effects of vision loss.
Call us now for a free case review.
Yes, it can. Some people experience blurred vision, and in rare cases, it has been linked to a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which damages the optic nerve. If you already deal with diabetes-related eye issues, Ozempic may make them worse, so regular eye checkups are a good idea.
Yes, but it’s uncommon. Studies suggest Ozempic can raise the risk of a condition that cuts off blood flow to the optic nerve, which can cause permanent vision loss. Most people won’t run into this, but sudden changes in vision should always be taken seriously.
Yes, there have been cases reported. Vision loss usually happens because of optic nerve damage. Unfortunately, it can be permanent in one eye. Some people have already filed lawsuits over this, saying they weren’t warned about the risk.
You might qualify, if you took Ozempic (or similar drugs like Wegovy or Rybelsus) and later developed serious health problems. This includes things like stomach paralysis, bowel blockages, gallbladder issues, or vision loss. Our lawyer can go over your medical history and let you know if you have a case.
That depends on your situation. People with severe injuries like permanent vision loss or serious stomach problems have seen cases in the hundreds of thousands, sometimes higher. The amount usually comes down to medical costs, lost wages, and how much the condition has affected daily life.
Nicholas began his post-graduate career clerking for the Honorable Linda Rovder Fleming in the Cambria County Court of Common Pleas. From there, he quickly found his calling in workers’ compensation, personal injury, and Social Security disability law—areas where he could directly impact people’s lives in moments of crisis. He’s helped clients navigate complex legal claims, including securing a settlement exceeding $300,000.
Nicholas brings clear communication, genuine empathy, and an unrelenting drive to achieve the best outcomes for his clients. Whether he’s navigating a complex workers’ comp claim or pushing for a major settlement, he brings focus, dedication, and deep legal knowledge to every case.
He’s also a proud member of Pennsylvania Advocates for Justice and remains active in various professional legal organizations. Nicholas is licensed to practice law in Pennsylvania.
When he’s not fighting for the injured, Nicholas is enjoying time with his family, kicking a soccer ball around, hitting the golf course, or cheering on Pittsburgh’s local teams.
Joe Ring heads the workers’ compensation department at Ethen Ostroff Law, where he takes pride in fighting for injured workers.
Joe is a Philadelphia native and maintains deep roots in the area. As the grandson of a Philadelphia Firefighter, son of a Philadelphia public school teacher, and veteran of the United State Marine Corps, he was taught to value service, dedication, and hard work. He applies these values to every case and takes great satisfaction in representing hard-working clients with those same traits.
After obtaining his bachelor’s degree in history from St. Vincent College in Western Pennsylvania, he graduated from Villanova Law School in 2012 and, since then, has litigated hundreds of workers’ compensation hearings and trial depositions on behalf of both employers and injured workers. During this time, Mr. Ring has written articles and presented Continuing Legal Education courses on developments in Pennsylvania Workers’ Compensation Law. He is active in local professional organizations, and, in 2022, he served a Co-chairperson of the Philadelphia Bar Associations Workers’ Compensation Section.
Since coming to EOL in 2024, he has dedicated his practice entirely to helping injured workers navigate the system and obtain their rightful benefits.
Joe is licensed to practice in Pennsylvania.
Brandon Zanan heads the personal injury claim department with Ethen Ostroff Law.
Brandon’s education in both law and medicine assist him in expertly representing badly injured victims. Brandon has a Master’s Degree in Forensic Medicine from the Philadelphia College of Osteopathic Medicine, with a concentration in anatomy and pathology. With this knowledge, Brandon is skilled at analyzing medical records and understanding injuries that are common in personal injury claims. He uses this expertise in conjunction with listening carefully to each client’s needs, in order to fiercely advocate for clients and tell their stories when they would not otherwise have a voice.
Brandon’s background includes a variety of experience and skills in various areas of civil practice. He is the author and editor of numerous books for the George T. Bisel Publishing Company, including “Pennsylvania Damages” and the “Pennsylvania Vehicle Code Annotated,” two texts that are frequently relied on by lawyers and judges across Pennsylvania as authoritative resources on personal injury law.
Brandon is a member of the Pennsylvania and Montgomery Bar Associations. He is also a member of Pennsylvania Association for Justice, and has served as an executive board member of the Montgomery American Inn of Court.
He is admitted to practice in the Commonwealth of Pennsylvania, the United States District Courts for the Eastern District of Pennsylvania and Middle District of Pennsylvania, the State of New Jersey, the United States District Court for the District of New Jersey, and in the Commonwealth of Virginia. Brandon has represented many clients in motor vehicle, premises liability, animal bite, and products liability cases across Pennsylvania and New Jersey and has obtained outstanding results with millions of dollars recovered for his clients.
He has been named a Pennsylvania Rising Star from 2021 onward. The “Super Lawyers-Rising Star®”, list recognizes no more than 2.5 percent of attorneys in each state
Brandon currently lives in Malvern with his wife Rachel and their son Max.
Effective Date: July 10, 2024
General Information
Welcome to the website of Ethen Ostroff Law, PLLC (“EO”). By accessing or using our website, you agree to be bound by these Terms and Conditions (“Terms”). If you do not agree with these Terms, please do not use our website.
Use
EO hereby grants you a non-exclusive, non-transferable, revocable, limited right and license to access and use the Site solely for your personal use in accordance with these Terms of Use. You shall not, in any way, otherwise copy, reproduce, distribute, transmit, display, perform, reproduce, publish, license, modify, create derivative works from, sell, or exploit the Site.
EO may at any time, for any reason, and without notice or liability: (a) modify, suspend, or terminate operation of or access to the Site and related services, or (b) change, revise, or modify the Site and affiliated services.
Messaging and Automated Calls
When you opt-in, you will receive text messages (SMS/MMS) on your mobile number. These messages may contain information about your case, and the message frequency may vary from user to user. Please note that message and data rates may apply. If you wish to opt out of this service, you can do so anytime by simply texting “STOP” to the phone number. Once you text “STOP” to us, we will send you an SMS to confirm that you have been unsubscribed. If you encounter any issues, you can reply with the keyword “HELP” to get assistance. Please be aware that carriers are not responsible for any delayed or undelivered messages.
By providing your phone number and submitting a form on our website, you consent to receive communications, including automated calls, texts, and pre-recorded messages, from EO and its affiliates. These communications may include updates about your case, promotional offers, and other information. You understand that these calls may be generated using automated technology, and that standard message and data rates may apply.
Your consent to receive automated calls is not a condition of any purchase or service. By checking the consent box on our contact form or by calling our firm, you agree to these Terms and Conditions and provide your written consent to receive these communications. You may opt out of these communications at any time by replying STOP to any text message or by contacting us at [insert contact information].
State-Specific Compliance
EO complies with all federal and state laws regarding automated calls and telemarketing practices. Certain states have additional restrictions on the use of automated dialing systems and pre-recorded messages. The following states have more restrictive regulations:
If you are a resident of one of these states, EO will obtain your prior express written consent before making any automated calls or sending pre-recorded messages to you.
By submitting a form inquiry or calling our firm, you agree to us contacting you, and your checking the box when submitting your form inquiry serves as written consent.
Information and Legal Disclaimer
The information contained in this website is for informational purposes only, and should not be construed as legal advice. Testimonials and case results contained in this website are for demonstrative purposes only, and do not constitute a guarantee of any particular outcome in a specific case.
By requesting a free consultation with Ethen Ostroff Law, PLLC, you agree to the following:
The law differs in every jurisdiction, and you should not rely on any opinion except that of an attorney you have retained, who has a professional duty to advise you after being fully informed of all the pertinent facts, and who is licensed in the applicable state, and is familiar with the applicable law. Internet subscribers, mobile application users, and online readers should seek professional counsel about their legal rights and remedies. You should not act or refrain from acting on the basis of any information found on the Site. Any actions or decisions about your legal rights should be based on the particular facts and circumstances of your situation, and appropriate legal advice from an attorney retained directly by you. EO EXPRESSLY DISCLAIMS ALL LIABILITY WITH RESPECT TO ACTIONS TAKEN OR NOT TAKEN BASED UPON ANY INFORMATION OR OTHER CONTENTS OF THIS SITE. Viewing the Site, or communicating with EO by Internet e-mail or through the Site does not constitute or create an attorney-client relationship with anyone. The content and features on the Site do not create, and are not intended to create, an attorney-client relationship, and shall not be construed as legal advice. The content and features of the Site, including means to submit a question or information, do not constitute an offer to represent you or otherwise give rise to an attorney/client relationship.
THE SITE IS PROVIDED “AS IS”. EO MAKES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE SITE AND ONLINE SERVICES AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND OR NATURE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, EO DOES NOT GUARANTEE THAT THE ONLINE SERVICES OR PRODUCTS WILL MEET YOUR REQUIREMENTS, OR WILL BE ERROR-FREE, UNINTERRUPTED, OR FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS, OR THAT ANY DEFECTS WILL BE CORRECTED.
Accounts
To use some features of the Site, you may be required to create an account. In connection therewith, you agree to provide and maintain true, accurate, current, and complete information about yourself. You are responsible for maintaining the confidentiality of the information you hold for your account login, including your password, and for all Submissions made from your account. You agree to notify us immediately of any unauthorized use of your login. EO may suspend access to your account if it suspects illegal or improper use, or for other reasons, such as for account management purposes, at its sole discretion.
Confidentiality is Not Guaranteed
Information sent to Ethen Ostroff Law, PLLC. via Internet e-mail or through the Site is not secure and is done on a non-confidential basis. EO may make reasonable efforts to keep communications private, but because of the nature of Internet communications and the absence of an attorney/client relationship, we cannot promise or guarantee confidentiality.
DISCLAIMER – This Site Does Not Provide Medical Diagnosis or Advice
The content provided on the Site, such as documents, text, graphics, images, videos, news alerts, pharmaceutical drug recalls, prescription medication history, or information on litigation concerning the foregoing topics, or other materials, is for informational purposes only. The information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a physician for diagnosis and treatment of any medical condition or for any questions you may have regarding a health concern. Never disregard professional medical advice, alter a prescription plan in any way, or delay or refrain from seeking medical advice because of something you have read or seen on the Site. Links to other sites are provided for information only. Use of trade names is for identification only and does not constitute endorsement by EO.
Without limiting the generality of the foregoing, the Site may present information about pharmaceutical drug recalls, which is for information purposes only. Such information is not necessarily the most current information on the subject and may or may not be updated based on the last information concerning such recalls. Do not make any decisions regarding medication or medical providers based on information from the Site, including but not limited to information we provide about drug recalls.
EO Is Not Responsible for Content; Limitation on Liability
EO may periodically change, remove, or add the material on the Site without notice. This material may contain technical or typographical errors. EO DOES NOT GUARANTEE ITS ACCURACY, COMPLETENESS OR SUITABILITY. EO assumes no liability or responsibility for any errors or omissions in the contents of the Site. Your use of the Site is at your own risk. Under no circumstances shall EO or any other party involved in the creation, production, or delivery of the Site be liable to you or any other person for any indirect, special, incidental, or consequential damages of any kind arising from your access to, or use of, the Site. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW IN NO EVENT SHALL EO BE LIABLE FOR ANY SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES RELATING TO THIS MATERIAL, FOR ANY USE OF THIS WEBSITE, OR FOR ANY OTHER LINKED WEBSITE.
Third-party Web Sites
The Site contains links to third-party websites for the convenience of our users. EO does not endorse any of these third-party sites and does not imply any association between EO and those sites. EO does not control these third-party websites and cannot represent that their policies and practices will be consistent with these Terms of Use. If you use links to access and use such websites, you do so at your own risk. EO is not responsible for the contents or availability of any linked sites. These links are provided only as a convenience to the recipient. These Terms only apply to the Site and do not apply to any linked sites. We encourage you to read and understand the terms of use of any linked sites that you visit. Links do not imply that we sponsor, endorse, are affiliated with or associated with, or are legally authorized to use any trademark, trade name, service mark, design, logo, symbol, or other copyrighted materials displayed on or accessible through any linked site.
EO Clients
Only individuals who have entered into a mutually signed retainer agreement with EO are EO clients (“EO Clients”).
Legal and Ethical Requirements
EO has tried to comply with all legal and ethical requirements in compiling the Site. We welcome comments about our compliance with the applicable rules and will update the Site as warranted, upon learning of any new or different requirements.
Ethen Ostroff Law reserves the right to refer or sell leads that come through any of Ethen Ostroff Law’s marketing.
Ethen Ostroff Law also may sell leads on certain campaigns generated in association with third party marketing companies.
Governing Laws in Case of Dispute; Jurisdiction
These Terms of Use shall be governed by and construed in accordance with the laws of the State of Pennsylvania, USA, without regard to any choice of law principles. Any and all disputes arising hereunder shall be governed as set forth in the Arbitration section below.
Submissions
You are solely responsible for any information, content, or material you transmit to or through the Site (“Submissions”). You understand that Submissions are considered non-confidential and non-proprietary. Furthermore, you grant EO an unrestricted, irrevocable, perpetual, transferable, sublicensable, worldwide, royalty-free license to use, copy, reproduce, display, publish, publicly perform, transmit, and distribute any Submission, without compensation or accounting to you or anyone else. You represent and warrant that: (a) you have the right to submit the Submission to EO and grant the licenses as described above; (b) EO will not need to obtain licenses from any third party or pay royalties to any third party for its use of the Submission; (c) the Submission does not infringe any third party’s rights, including intellectual property rights and privacy rights; and (d) the Submission complies with these Terms of Use and all applicable laws and regulations.
EO takes no responsibility and assumes no liability for any Submission.
Arbitration
Any and all claims by you arising out of or related to the Site or your use thereof may be resolved only through a binding arbitration proceeding to be conducted under the auspices of the Commercial Arbitration Rules of the American Arbitration Association in Montgomery County, Pennsylvania. Both your agreement to arbitrate all controversies, disputes and claims, and the results and awards rendered through the arbitration, will be final and binding on you and may be specifically enforced by legal proceedings. Arbitration will be the sole means of resolving such controversies, disputes and claims, and you waive your rights to resolve such controversies, disputes and claims by court proceedings or any other means. You agree that judgment may be entered on the award in any court of competent jurisdiction and, therefore, any award rendered shall be binding. The arbitrator may not consolidate more than one person’s claims, and may not otherwise preside over any form of a representative or class proceeding. You understand that by agreeing to arbitration as a mechanism to resolve all controversies, disputes and claims between us, you are waiving certain rights, including the right to bring an action in court, the right to a jury trial, the right to broad discovery, and the right to an appeal. You understand that in the context of arbitration, a case is decided by an arbitrator (one or more), not by a judge or a jury.
International Use
The Site is controlled, operated, and administered by EO from offices within the United States of America and is only intended for use therein. We make no representation regarding use of the Site outside of the United States.
Other Terms
If, for any reason, our Terms of Use, Privacy Policy, or any portion thereof to be unenforceable, such provision shall be enforced to the maximum extent permissible so as to give the intended effect thereof, and the remainder of these Terms of Use and Privacy Policy shall continue in full force and effect. EO’s failure to act with respect to a breach by you or others does not waive our right to act with respect to that breach or subsequent or similar breaches. No consent or waiver by EO hereof will be deemed effective unless in writing. These Terms of Use, together with our Privacy Policy, as each is currently posted, constitute the entire agreement between EO and you with respect to your use of the Site and supersede all previous written or oral agreements relating to the subject matter hereof, that this agreement shall not supersede, restrict, or replace any agreements governing the attorney-client relationship between EO and EO Clients.
EO may, in its sole discretion and without prior notice, block and/or terminate your access to the Site and if we determine that you have violated these Terms of Use or other terms or agreements or that may be associated therewith or if you use the Site in a way that we deem, in our sole discretion, to be an unacceptable use.
